Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KYTXNYSE:NNVCNASDAQ:ORMPNASDAQ:ZNTL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYTXKyverna Therapeutics$2.27-8.1%$2.12$1.78▼$16.64$98.11M2.17421,119 shs524,822 shsNNVCNanoViricides$1.79+20.9%$1.28$0.94▼$3.59$28.77M0.95252,096 shs979,081 shsORMPOramed Pharmaceuticals$2.12-1.4%$2.22$1.82▼$3.09$86.60M1.65153,120 shs21,385 shsZNTLZentalis Pharmaceuticals$1.20-3.2%$1.38$1.01▼$13.00$86.34M1.811.56 million shs778,244 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYTXKyverna Therapeutics0.00%-2.16%+6.07%-18.35%-82.97%NNVCNanoViricides0.00%+26.95%+32.59%+19.33%-19.73%ORMPOramed Pharmaceuticals0.00%-1.40%-7.83%-1.40%-7.83%ZNTLZentalis Pharmaceuticals0.00%-4.76%-20.53%-48.28%-89.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKYTXKyverna Therapeutics2.1396 of 5 stars3.53.00.00.02.51.70.0NNVCNanoViricidesN/AN/AN/AN/AN/AN/AN/AN/AORMPOramed Pharmaceuticals2.1422 of 5 stars0.05.00.00.02.80.81.9ZNTLZentalis Pharmaceuticals1.7507 of 5 stars3.21.00.00.02.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKYTXKyverna Therapeutics 3.00Buy$18.33707.64% UpsideNNVCNanoViricides 0.00N/AN/AN/AORMPOramed Pharmaceuticals 2.00HoldN/AN/AZNTLZentalis Pharmaceuticals 2.44Hold$8.24587.04% UpsideCurrent Analyst Ratings BreakdownLatest NNVC, ZNTL, KYTX, and ORMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ZNTLZentalis PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.005/15/2025ZNTLZentalis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/3/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $4.004/1/2025KYTXKyverna TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $20.003/28/2025ZNTLZentalis PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.003/27/2025ZNTLZentalis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/17/2025ZNTLZentalis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKYTXKyverna Therapeutics$7.03M13.96N/AN/AN/A∞NNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/AORMPOramed Pharmaceuticals$2M43.30N/AN/A$4.04 per share0.52ZNTLZentalis Pharmaceuticals$26.87M3.21N/AN/A$6.18 per share0.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKYTXKyverna Therapeutics-$60.37M-$3.38N/AN/AN/AN/A-51.12%-37.91%8/11/2025 (Estimated)NNVCNanoViricides-$8.29M-$0.70N/A∞N/AN/A-87.90%-78.69%N/AORMPOramed Pharmaceuticals$5.53M-$0.4419.27N/AN/AN/A-7.27%-6.20%8/13/2025 (Estimated)ZNTLZentalis Pharmaceuticals-$292.19M-$3.13N/AN/AN/AN/A-43.91%-34.96%8/8/2025 (Estimated)Latest NNVC, ZNTL, KYTX, and ORMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ORMPOramed Pharmaceuticals-$0.03-$0.19-$0.16-$0.19N/A$2.00 million5/14/2025Q1 2025ZNTLZentalis Pharmaceuticals-$0.67-$0.67N/A-$0.67N/AN/A5/13/2025Q1 2025KYTXKyverna Therapeutics-$1.21-$1.03+$0.18-$1.03N/AN/A3/27/2025Q4 2024KYTXKyverna Therapeutics-$0.87-$0.88-$0.01-$0.88N/AN/A3/27/2025Q4 2024ORMPOramed Pharmaceuticals-$0.03$0.01+$0.04$0.01N/AN/A3/26/2025Q4 2024ZNTLZentalis Pharmaceuticals-$0.75-$0.66+$0.09-$0.66N/A$26.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKYTXKyverna TherapeuticsN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/AZNTLZentalis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKYTXKyverna TherapeuticsN/A10.5010.50NNVCNanoViricidesN/A3.442.47ORMPOramed PharmaceuticalsN/A27.0827.08ZNTLZentalis PharmaceuticalsN/A7.297.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKYTXKyverna Therapeutics18.08%NNVCNanoViricides10.30%ORMPOramed Pharmaceuticals12.73%ZNTLZentalis PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipKYTXKyverna Therapeutics22.00%NNVCNanoViricides4.60%ORMPOramed Pharmaceuticals13.70%ZNTLZentalis Pharmaceuticals1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKYTXKyverna Therapeutics9643.22 millionN/AOptionableNNVCNanoViricides2016.07 million14.92 millionOptionableORMPOramed Pharmaceuticals1040.85 million34.79 millionOptionableZNTLZentalis Pharmaceuticals16071.95 million68.70 millionOptionableNNVC, ZNTL, KYTX, and ORMP HeadlinesRecent News About These CompaniesZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of "Hold" by AnalystsMay 25 at 1:31 AM | marketbeat.comJacobs Levy Equity Management Inc. Takes $703,000 Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)May 20, 2025 | marketbeat.comHC Wainwright Brokers Raise Earnings Estimates for ZNTLMay 20, 2025 | marketbeat.comWedbush Issues Optimistic Outlook for ZNTL EarningsMay 20, 2025 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Neutral Rating from WedbushMay 18, 2025 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)May 17, 2025 | americanbankingnews.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by MPM Bioimpact LLCMay 16, 2025 | marketbeat.comZentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational ProgressMay 14, 2025 | globenewswire.comIntegral Health Asset Management LLC Makes New Investment in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)May 14, 2025 | marketbeat.comAlmitas Capital LLC Raises Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)May 4, 2025 | marketbeat.comBoxer Capital Management LLC Makes New $1.36 Million Investment in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)May 4, 2025 | marketbeat.comFirst Patient Dosed With Azenosertib in Cyclin E1+ Ovarian CancerMay 3, 2025 | curetoday.comZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | globenewswire.comZentalis Pharmaceuticals (ZNTL) to Release Earnings on TuesdayMay 1, 2025 | marketbeat.comScott Dunseth Myers Purchases 21,000 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) StockMay 1, 2025 | insidertrades.comZentalis shares insights on cancer research at AACRApril 29, 2025 | investing.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of "Hold" by BrokeragesApril 29, 2025 | marketbeat.comZentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROCApril 28, 2025 | globenewswire.comDecheng Capital LLC Trims Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)April 28, 2025 | marketbeat.comWalleye Capital LLC Makes New $587,000 Investment in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)April 25, 2025 | marketbeat.comJPMorgan Chase & Co. Boosts Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)April 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNNVC, ZNTL, KYTX, and ORMP Company DescriptionsKyverna Therapeutics NASDAQ:KYTX$2.27 -0.20 (-8.10%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.26 -0.01 (-0.44%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.NanoViricides NYSE:NNVC$1.79 +0.31 (+20.95%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.79 0.00 (0.00%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.Oramed Pharmaceuticals NASDAQ:ORMP$2.13 -0.02 (-0.70%) As of 05/23/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.Zentalis Pharmaceuticals NASDAQ:ZNTL$1.20 -0.04 (-3.23%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.22 +0.02 (+1.58%) As of 05/23/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Alphabet Stock Lags—But Waymo May Be Its Hidden Driver This Market Sell-Off Might Trigger a Value Rotation Into Pepsi Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
